Aurobindo Pharma to produce generic Molnupiravir at domestic manufacturing facilities

29 Dec 2021 Evaluate

Aurobindo Pharma is planning to produce generic version of the antiviral drug Molnupiravir at its domestic manufacturing facilities which have been approved by global agencies like the USFDA and UKMHRA. Molnupiravir is used in the treatment of COVID-19. The company would sell the product under the brand 'Molnaflu' and has adequate capacities to meet the global demand across the 100 plus Low and Middle-Income Countries (LMIC).

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Aurobindo Pharma Share Price

1217.45 -6.20 (-0.51%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×